The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
Feature|Articles|September 18, 2025
- Vol.26/No.12
- Volume 26
- Issue 12
Targeted Therapies Drive Demand for Comprehensive Biomarker Testing in NSCLC
Author(s)Ashling Wahner
Fact checked by: Chris Ryan, Tracy Ann Politowicz
Lung cancer experts share the evolution of biomarker testing that has led to advances in patient selection for treatment, as well as challenges that future developments may address.
Advertisement
Advertisement
The non–small cell lung cancer (NSCLC) treatment paradigm has welcomed the addition of numerous targeted therapies over the past several years, prompting a complementary increase in molecular testing rates and innovative tumor sequencing methods. However, persisting barriers to testing, such as tissue insufficiency, emphasize the need for increased diligence through repeat biopsies and improved testing alternatives such as liquid biopsies, according to lung cancer experts interviewed by OncLive®.
Related to this article
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
Advertisement
Advertisement